JP2005508337A5 - - Google Patents

Download PDF

Info

Publication number
JP2005508337A5
JP2005508337A5 JP2003530699A JP2003530699A JP2005508337A5 JP 2005508337 A5 JP2005508337 A5 JP 2005508337A5 JP 2003530699 A JP2003530699 A JP 2003530699A JP 2003530699 A JP2003530699 A JP 2003530699A JP 2005508337 A5 JP2005508337 A5 JP 2005508337A5
Authority
JP
Japan
Prior art keywords
hydrogen
alkyl
compound
halogen
physiologically functional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003530699A
Other languages
English (en)
Other versions
JP2005508337A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/030150 external-priority patent/WO2003027111A1/en
Publication of JP2005508337A publication Critical patent/JP2005508337A/ja
Publication of JP2005508337A5 publication Critical patent/JP2005508337A5/ja
Pending legal-status Critical Current

Links

Claims (6)

  1. 式(I):
    Figure 2005508337
    [式中、
    XはNであり、ZはCHであるか;又は、
    XはCHであり、ZはNであり;
    Rは水素又はハロゲンであり;
    Aは、
    Figure 2005508337
    (式中、
    R1はハロゲンであり、
    R2は水素、C1-C6-アルキル、C1-C6-アルコキシ又はC1-C6-アルキルスルファニルであり、
    R3は水素又はC1-C6-アルキルである)
    から選択される]
    で表される化合物並びにその塩、溶媒和物及び生理学的に機能する誘導体。
  2. Aが、
    Figure 2005508337
    であり、R1がハロゲンであり、R2が水素、C1-C6-アルキル、C1-C6-アルコキシ又はC1-C6-アルキルスルファニルである、請求項1に記載の化合物。
  3. Aが、
    Figure 2005508337
    であり、R3が水素又はC1-C6-アルキルである、請求項1に記載の化合物。
  4. 以下の
    Figure 2005508337
    から選択される化合物。
  5. 治療有効量の請求項1〜4のいずれか1項に記載の化合物又はその塩、溶媒和物若しくは生理学的に機能する誘導体及び1種以上の医薬上許容される担体、希釈剤及び賦形剤を含む医薬組成物。
  6. 不適切TrkA活性が介在する疾患の治療で使用されるための医薬の製造における請求項1〜5のいずれか1項に記載の化合物又はその塩、溶媒和物若しくは生理学的に機能する誘導体の使用。
JP2003530699A 2001-09-27 2002-09-24 化合物 Pending JP2005508337A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32601201P 2001-09-27 2001-09-27
PCT/US2002/030150 WO2003027111A1 (en) 2001-09-27 2002-09-24 Chemical compounds

Publications (2)

Publication Number Publication Date
JP2005508337A JP2005508337A (ja) 2005-03-31
JP2005508337A5 true JP2005508337A5 (ja) 2005-12-22

Family

ID=23270442

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003530699A Pending JP2005508337A (ja) 2001-09-27 2002-09-24 化合物

Country Status (7)

Country Link
US (2) US7015231B2 (ja)
EP (1) EP1430053B1 (ja)
JP (1) JP2005508337A (ja)
AT (1) ATE343575T1 (ja)
DE (1) DE60215682T2 (ja)
ES (1) ES2275021T3 (ja)
WO (1) WO2003027111A1 (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508366A (ja) 2000-09-01 2004-03-18 グラクソ グループ リミテッド オキシインドール誘導体
US7071217B2 (en) 2000-09-01 2006-07-04 Smithkline Beecham Corporation Substituted oxindole derivatives as tyrosine kinase inhibitors
DE60215682T2 (de) * 2001-09-27 2007-09-06 Smithkline Beecham Corp. AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ
ATE530545T1 (de) 2005-02-04 2011-11-15 Astrazeneca Ab Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate
DK1853602T3 (da) * 2005-02-16 2010-09-20 Astrazeneca Ab Kemiske forbindelser
ES2308731T3 (es) 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
ES2391783T3 (es) 2005-10-28 2012-11-29 Astrazeneca Ab Derivados de 4-(3-aminopirazol)pirimidina para su uso como agentes inhibidores de las tirosina cinasas en el tratamiento del cáncer
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CA2649043C (en) 2006-04-19 2013-09-17 Astellas Pharma Inc. Azolecarboxamide derivative
PL2206707T3 (pl) 2007-10-24 2015-01-30 Astellas Pharma Inc Związek azolokarboksamidowy lub jego sól
EP2292089A1 (en) 2008-01-11 2011-03-09 Astellas Pharma Inc. Model animal having both pain in testis or testis-related discomfort actions and frequent urination
WO2010077680A2 (en) * 2008-12-08 2010-07-08 Vm Discovery Inc. Compositions of protein receptor tyrosine kinase inhibitors
BR112012025343A2 (pt) * 2010-04-15 2016-06-28 Merck Patent Gmbh processo para a preparação de hidroquinonas
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
CN103804273B (zh) * 2014-01-27 2016-06-15 贵州大学 氧化吲哚与茚三酮双季碳拼接衍生物及其制备方法
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
US10301271B2 (en) 2014-09-17 2019-05-28 Purdue Pharma L.P. Crystalline forms of tyrosine kinase inhibitors and their salts
WO2016089760A1 (en) 2014-12-02 2016-06-09 Ignyta, Inc. Combinations for the treatment of neuroblastoma
CA3008663A1 (en) 2015-12-18 2017-06-22 Ignyta, Inc. Combinations of a selective tyrosine kinase inhibitor (tki) with a mek or erk inhibitor for the treatment of cancer
BR112020000793A2 (pt) 2017-07-19 2020-07-14 Ignyta, Inc. composições farmacêuticas e formas de dosagem
WO2019077506A1 (en) 2017-10-17 2019-04-25 Ignyta, Inc. PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9423997D0 (en) * 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
WO2000008202A2 (en) * 1998-08-04 2000-02-17 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
DE60215682T2 (de) * 2001-09-27 2007-09-06 Smithkline Beecham Corp. AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ

Similar Documents

Publication Publication Date Title
JP2005508337A5 (ja)
JP2006523216A5 (ja)
JP2021100937A5 (ja)
JP2006526590A5 (ja)
JP2004517099A5 (ja)
JP2004517049A5 (ja)
JP2006182786A5 (ja)
JP2020507589A5 (ja)
JP2004516314A5 (ja)
JP2006509749A5 (ja)
JP2004509061A5 (ja)
WO2006098918A3 (en) Substituted gamma lactams as therapeutic agents
JP2008526999A5 (ja)
RU2005107314A (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью
JP2008513510A5 (ja)
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
JP2003503449A5 (ja)
JP2008500378A5 (ja)
JP2004517098A5 (ja)
JP2009506043A5 (ja)
JP2002525323A5 (ja)
JP2019533660A5 (ja)
JP2005513014A5 (ja)
IL150817A0 (en) Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases
JP2005538974A5 (ja)